

Spark Therapeutics, Inc.  
Form SC TO-C  
February 25, 2019

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE TO**

**Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of  
the Securities Exchange Act of 1934**

**SPARK THERAPEUTICS, INC.**

*(Name of Subject Company)*

**022019 MERGER SUBSIDIARY, INC.**

*(Offeror)*

*A Wholly Owned Subsidiary of*

**ROCHE HOLDINGS, INC.**

*(Parent of Offeror)*

*(Names of Filing Persons – Offeror)*

**Common Stock, Par Value \$0.001 Per Share**

*(Title of Class of Securities)*

**84652J103**

*(Cusip Number of Class of Securities)*

**Bruce Resnik**

**Roche Holdings, Inc.**

**1 DNA Way, MS #24,**

**South San Francisco, CA 94080**

**Telephone: (650) 225-1000**

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)*

***Copies to:***

**Marc O. Williams**

**Brian Wolfe**

**Davis Polk & Wardwell LLP**

**450 Lexington Avenue**

**New York, New York 10017**

**Telephone: (212) 450-4000**

**CALCULATION OF FILING FEE**

Transaction Valuation*	Amount of Filing Fee**
N/A	N/A

\* A filing fee is not required in connection with this filing as it relates solely to preliminary communications made before the commencement of the tender offer

Check box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid: Not applicable. Filing Party: Not applicable.  
Form or Registration No.: Not applicable Date Filed: Not applicable.

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

☒ third-party tender offer subject to Rule 14d-1.

☐ issuer tender offer subject to Rule 13e-4.

☐ going-private transaction subject to Rule 13e-3.

☐ amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer. ☐

**EXHIBIT INDEX**

**Exhibit No. Description**

- |      |  |
|------|--|
| 99.1 | Media Release issued by Roche Holdings, Inc. on February 25, 2019. |
| 99.2 | Key Messages and Q&A dated February 25, 2019.                      |